Orion Oyj (OTCMKTS:ORINY) Short Interest Up 25.0% in November

Orion Oyj (OTCMKTS:ORINY) saw a significant growth in short interest during the month of November. As of November 15th, there was short interest totalling 500 shares, a growth of 25.0% from the October 31st total of 400 shares. Based on an average daily volume of 100 shares, the days-to-cover ratio is currently 5.0 days.

Orion Oyj Price Performance

OTCMKTS ORINY opened at $23.40 on Monday. The stock has a market capitalization of $6.61 billion, a price-to-earnings ratio of 18.57 and a beta of 0.22. Orion Oyj has a 1-year low of $17.50 and a 1-year high of $28.55. The company has a debt-to-equity ratio of 0.31, a current ratio of 2.39 and a quick ratio of 1.29. The business’s fifty day moving average price is $25.32 and its 200-day moving average price is $23.76.

Orion Oyj (OTCMKTS:ORINY) last posted its earnings results on Tuesday, October 29th. The company reported $0.63 earnings per share for the quarter. Orion Oyj had a return on equity of 41.41% and a net margin of 23.01%. The company had revenue of $517.97 million for the quarter. On average, equities analysts predict that Orion Oyj will post 1.26 earnings per share for the current year.

Orion Oyj Cuts Dividend

The firm also recently declared a dividend, which was paid on Thursday, November 7th. Shareholders of record on Wednesday, October 16th were given a $0.2405 dividend. The ex-dividend date of this dividend was Wednesday, October 16th. Orion Oyj’s payout ratio is presently 26.98%.

About Orion Oyj

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides prescription drugs and self-care products, which includes Nubeqa for the treatment of prostate cancer; Precedex, Dexdor, and Precedex for human use; Burana for inflammatory pain; Divina series for menopausal symptoms; Trexan for rheumatoid arthritis and cancer; Stalevo, Entacapone, and Comtess/Comtan for Parkinson’s disease; Biosimilars for rheumatoid arthritis and inflammatory bowel diseases; and Simdax for acute decompensated heart failure, as well as Fareston for breast cancer.